Supplementary Table 1 PRISMA 2020 checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	Abstract 2 See the PRISMA 2020 for Abstracts checklist.		Page 2-3
INTRODUCTIO	N		
Rationale	onale 3 Describe the rationale for the review in the context of existing knowledge.		Page 3-5
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	
METHODS	1		
Eligibility	igibility 5 Specify the inclusion and exclusion criteria for the review and how studies were grouped for		Page 5
criteria	riteria the syntheses.		
Information	Information 6 Specify all databases, registers, websites, organisations, reference lists and other sources		Page 5-6
sources		searched or consulted to identify studies. Specify the date when each source was last searched	
	or consulted.		
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters	

Section and Topic	Item #	Checklist item	
		and limits used.	
Selection	8	Specify the methods used to decide whether a study met the inclusion criteria of the review,	Page 6
process		including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	
Data collection	9	Specify the methods used to collect data from reports, including how many reviewers	Page 6
process		collected data from each report, whether they worked independently, any processes	
		obtaining or confirming data from study investigators, and if applicable, details of automatic	
		tools used in the process.	
Data items	ata items 10a List and define all outcomes for which data were sought. Specify whether all results that we		Page 5-6
		compatible with each outcome domain in each study were sought (e.g. for all measures, time	
		points, analyses), and if not, the methods used to decide which results to collect.	
	10b	List and define all other variables for which data were sought (e.g. participant and	Page 5-6
		intervention characteristics, funding sources). Describe any assumptions made about any	
		missing or unclear information.	
Study risk of	11	Specify the methods used to assess risk of bias in the included studies, including details of the	Page 6-7
bias assessment tool(s) used, how many reviewers assessed each study and whether they w		tool(s) used, how many reviewers assessed each study and whether they worked	

Section and Topic	Item #	Checklist item	
		independently, and if applicable, details of automation tools used in the process.	
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 7
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 7-9
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	

Section and Topic	Checklist item		Location where item is reported
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	
Certainty assessment			Page 11
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 9
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 9
Study	17 Cite each included study and present its characteristics.		Page 9
characteristics	characteristics		and table
Risk of bias in studies			Page 9 and Table

Section Topic	and	Item #	Checklist item	
				2
Results	of	19	For all outcomes, present, for each study: (a) summary statistics for each group (where	NA
individual			appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval),	
studies			ideally using structured tables or plots.	
Results	of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing	Page 9-10
syntheses			studies.	
		20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for	
			each the summary estimate and its precision (e.g. confidence/credible interval) and measures	
			of statistical heterogeneity. If comparing groups, describe the direction of the effect.	
		20c	Present results of all investigations of possible causes of heterogeneity among study results.	
		20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized	
			results.	
Reporting		21	Present assessments of risk of bias due to missing results (arising from reporting biases) for	10
biases			each synthesis assessed.	
Certainty	of	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome	11

Section and Topic	Item #	Checklist item	Location where item is reported
evidence		assessed.	
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 10-
	23b	Discuss any limitations of the evidence included in the review.	12
	23c	Discuss any limitations of the review processes used.	
	23d Discuss implications of the results for practice, policy, and future research.		
OTHER INFOR	MATIC	ON CONTRACTOR OF THE PROPERTY	
Registration	24a	Provide registration information for the review, including register name and registration	Page 5
and protocol		number, or state that the review was not registered.	
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	
	24c	Describe and explain any amendments to information provided at registration or in the	
		protocol.	
Support	25	Describe sources of financial or non-financial support for the review, and the role of the	Page 12
		funders or sponsors in the review.	
Competing	26	Declare any competing interests of review authors.	Page 12

Section and Topic	Item #	Checklist item	Location where item is reported
interests			
Availability of	vailability of 27 Report which of the following are publicly available and where they can be found: template		Page 12
data, code and	data, code and data collection forms; data extracted from included studies; data used for all analyses; analytic		
other materials		code; any other materials used in the review.	

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

Supplementary Table 2 Database search strings

Name of the		No. of	
database	Search string	articles	Electronic link
uatabase		retrieved	
	(((((("vitamin D"[Title/Abstract]) OR (calciferol[Title/Abstract])) OR ("vitamin		
	D2"[Title/Abstract])) OR (ergocalciferol[Title/Abstract])) OR ("vitamin	367	Timb1
	D3"[Title/Abstract])) OR (cholecalciferol[Title/Abstract])) AND	307	<u>Link</u> ¹
Drafa Mod	((gdm[Title/Abstract]) OR ("gestational diabetes"[Title/Abstract]))		
PubMed	("diabetes, gestational"[MeSH Terms]) AND ("vitamin D"[Title/Abstract] OR		
	"calciferol"[Title/Abstract] OR "vitamin D2"[Title/Abstract] OR	100	<u>Link</u> ¹
	"ergocalciferol"[Title/Abstract] OR "vitamin D3"[Title/Abstract] OR	180	
	"cholecalciferol"[Title/Abstract])		
г 1	('vitamin d':ab,ti OR ergocalciferol:ab,ti OR cholecalciferol:ab,ti) AND gdm:ab,ti OR	204	-
Embase	'pregnancy diabetes mellitus':ab,ti	384	
	TITLE-ABS ("vitamin D") OR TITLE-ABS (ergocalciferol) OR TITLE-ABS		
Scopus	(cholecalciferol) AND TITLE-ABS (gdm) OR TITLE-ABS (gestational AND	426	-
	diabetes)		

¹The no. of articles retrieved might vary on replication as newly indexed studies in PubMed will populate in the search output